Disclosure: S. Lockhart, N. Ayakta, J. Winer, and R. La Joie report no disclosures relevant to the manuscript. G. Rabinovici receives research support from Avid Radiopharmaceuticals, GE Healthcare, and Piramal, and has received consulting fees or speaking honoraria from Roche, Eisai, Lundbeck, Piramal, and Putnam. W. Jagust has served as a consultant to BioClinica, Genentech, and Novartis Pharmaceuticals. Avid Radiopharmaceuticals enabled use of the ^{18}F -AV-1451 tracer but did not provide direct funding and was not involved in data analysis or interpretation. Go to Neurology.org for full disclosures.

Received September 22, 2016. Accepted in final form December 9, 2016.
Correspondence to Dr. Lockhart: snl@berkeley.edu

© 2017 American Academy of Neurology

1. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. *Ann Neurol* 2015;78:787–800.
2. Xia CF, Arteaga J, Chen G, et al. [^{18}F]T807, a novel tau positron emission tomography imaging agent for

Alzheimer's disease. *Alzheimers Dement* 2013;9:666–676.

3. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. *Acta Neuropathol Commun* 2016;4:58.
4. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. *Ann Neurol* 2016;79:110–119.
5. Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. *Neuron* 2016;89:971–982.
6. Uchihara T, Tsuchiya K, Nakamura A, Ikeda K. Appearance of tau-2 immunoreactivity in glial cells in human brain with cerebral infarction. *Neurosci Lett* 2000;286:99–102.
7. Uchihara T, Tsuchiya K, Kondo H, Hayama T, Ikeda K. Widespread appearance of Alz-50 immunoreactive neurons in the human brain with cerebral infarction. *Stroke* 1995;26:2145–2148.

Nicolas Molko, MD, PhD
Olivier Simon, MD
David Guyon, MD
Antoine Biron, PharmD
Myrielle Dupont-Rouzeyrol, PhD
Ann-Claire Gourinat, PharmD

ZIKA VIRUS INFECTION AND MYASTHENIA GRAVIS: REPORT OF 2 CASES

Zika virus (ZIKV) infection is known as a benign infection usually presenting as an influenza-like illness.¹ However, clusters of microcephaly cases and other neurologic disorders following ZIKV outbreaks in Brazil, as well as a cluster of Guillain-Barré syndrome following an outbreak in French Polynesia in 2014, constitute a Public Health Emergency of International Concern according to WHO.^{2,3} An outbreak of ZIKV infection in New Caledonia occurred in 2014 with 1,380 confirmed cases within a population of 263,000.⁴ We report 2 cases of myasthenia gravis (MG) with prior ZIKV infection.

Patient 1. A previously healthy 45-year-old man developed an influenza-like illness in February 2014, associated with headache, arthralgia, and severe asthenia for 1 week. Diagnosis of ZIKV infection was confirmed by real-time reverse-transcriptase PCR (RT-PCR) performed on serum.⁵ Two and a half months later, the patient had fluctuating weakness of the limbs with areflexia and ptosis of the left eye. Sensory examination results were normal. A significant decrement of the trapezius muscle to repetitive nerve stimulation was found. Edrophonium test was negative. Acetylcholine receptor (AChR) antibodies were markedly elevated at 80 mmol/L (normal <0.2). CT scan of the mediastinum showed a 28 × 34 × 26 mm thymoma. The patient responded to initial treatment with pyridostigmine and IV immunoglobulins. He was then treated with prednisone and azathioprine and developed pharmacologic remission. Thymectomy was performed 6 months later after complete clinical remission and showed a grade I thymoma.

Patient 2. A 62-year-old man, with a history of colon cancer and benign thymoma in 2008, presented with fever, diarrhea, and dyspnea in May 2014 and was positive by RT-PCR for ZIKV performed on serum.⁵ Two months later, he had a myasthenic crisis with generalized weakness and respiratory failure, requiring immediate respiratory assistance. Some weakness of voluntary muscles and diplopia were already present 1 week before admission to the intensive care unit (ICU). AChR antibodies were elevated at 80 mmol/L (normal <0.2). Repetitive nerve stimulation studies confirmed a defect in neuromuscular transmission. CT scan of the mediastinum showed a 40 × 55 × 46 mm thymoma of unchanged size compared to 2008. No clinical improvement was initially observed under pyridostigmine and IV immunoglobulins. Prolonged mechanical ventilation was associated with complications of ICU care (infections, cardiac arrhythmia, psoas hematoma). The patient improved slowly under IV methylprednisolone, and weaning from the mechanical ventilation was performed 1.5 months later. Symptoms of MG were then controlled on azathioprine and prednisone. Four months later, the patient experienced a mild relapse related to prednisone tapering. Pharmacologic remission occurred 6 months later. Thymectomy was performed 1.5 years later and showed a grade I thymoma.

Discussion. We report 2 cases of MG occurring 8–10 weeks after ZIKV infection. The presence of a thymoma in these 2 patients suggests a longstanding host predisposition to MG and is already a pathologic event. Whether ZIKV infection is coincidental, initiates MG, or provokes symptomatic disease in a previously unrecognized MG remains unknown. During ZIKV outbreaks, several autoimmune complications

(Guillain-Barré syndrome, thrombocytopenic purpura) have been described.^{2,3} In this context and since MG is rare, the potential role of ZIKV infection as a trigger of MG should be investigated. The factors that initiate the autoimmune response in MG are unknown and may result from a mix of genetics, environmental factors, and stochastic events. Interestingly, after West Nile virus infection, a closely related flavivirus, 6 cases of MG have been reported 3–7 months after the infection, including 1 patient with a thymoma.⁶ Since MG may mimic Guillain-Barré syndrome, clinicians should be aware of the putative risk of MG following ZIKV infection.

From Territorial Hospital (N.M., O.S., D.G.); and Institut Pasteur in New Caledonia (A.B., M.D.-R., A.-C.G.), Institut Pasteur International Network, Noumea, New Caledonia.

Author contributions: Nicolas Molko searched the literature and drafted the article. Olivier Simon revised the article critically for intellectual content. David Guyon revised the article critically for intellectual content. Antoine Biron revised the article critically for intellectual content. Myrielle Dupont-Rouzeyrol revised the article critically for intellectual content. Ann-Claire Gourinat revised the article critically for intellectual content.

Study funding: No targeted funding reported.

Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received August 9, 2016. Accepted in final form December 19, 2016.

Correspondence to Dr. Molko: n.molko@cbl.nc

© 2017 American Academy of Neurology

1. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med* 2009;360:2536–2543.
2. Samarasakera U, Triunfol M. Concern over Zika virus grips the world. *Lancet* 2016;387:521–524.
3. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *Lancet* 2016;387:1531–1539.
4. Dupont-Rouzeyrol M, O'Connor O, Calvez E, et al. Co-infection with Zika and Dengue viruses in 2 patients, New Caledonia, 2014. *Emerg Infect Dis* 2015; 21:381–382.
5. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis* 2008;14:1232–1239.
6. Leis AA, Szatmary G, Ross MA, Stokic DS. West Nile virus infection and myasthenia gravis. *Muscle Nerve* 2014;49:26–29.

Carry the Only Card that Helps Support the AAN—and Get a \$100 Cash Rewards Bonus!

Apply for the BankAmericard Cash Rewards™ credit card today to start getting more cash back for the things you buy most—plus a \$100 cash rewards bonus offer! Visit AAN.com/view/CashRewards and enter priority code “VACN51.”

Get 10 AAN Practice Management Webinars for Less than \$19 Each

The AAN is dedicated to helping neurologists improve their practices and delivery of quality care to their patients. Our popular Practice Management Webinars offer the latest expert information and insights to help you navigate through the changes that lay ahead in the new health care landscape. And they offer the flexibility to attend live webinars or access them on demand at a more convenient time.

Purchase webinars individually for \$99 each, or subscribe to the complete series of 2017 webinars for only \$189—that's less than \$19 per webinar! See the list of webinars and subscribe at AAN.com/view/pmw17.

Neurology®

Zika virus infection and myasthenia gravis: report of 2 cases

Nicolas Molko, Olivier Simon, David Guyon, et al.

Neurology 2017;88;1097-1098 Published Online before print February 10, 2017

DOI 10.1212/WNL.0000000000003697

This information is current as of February 10, 2017

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/88/11/1097.full
References	This article cites 6 articles, 0 of which you can access for free at: http://n.neurology.org/content/88/11/1097.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Clinical Neurology http://n.neurology.org/cgi/collection/all_clinical_neurology Burden of disease http://n.neurology.org/cgi/collection/burden_of_disease Myasthenia http://n.neurology.org/cgi/collection/myasthenia Post-infectious http://n.neurology.org/cgi/collection/postinfectious_ Public health http://n.neurology.org/cgi/collection/public_health Viral infections http://n.neurology.org/cgi/collection/viral_infections
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2017 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.